Loading clinical trials...
Loading clinical trials...
This is a Phase I, open-label, randomized study of NY-ESO-l protein with immune adjuvants CpG 7909 and Montanide ISA-51 VG in patients with tumors that often express NY-ESO-1. The vaccinations was to...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ludwig Institute for Cancer Research
Collaborators
NCT07539441 · Central Nervous System Tumors, Glioma
NCT04570423 · Solid Tumors, Lymphoma
NCT06926283 · Prostate Cancer, Other Solid Tumors, and more
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
NYU Clinical Cancer Center
New York, New York
NY Presbyterian- Columbia
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions